Morepen Laboratories profit drops 20% as margins tighten
Consolidated net profit fell to ₹94.88 crore on flat revenue of ₹1,805.69 crore for FY26. The board declared a final dividend of ₹0.20 per share.
— 1 earlier story on Morepen Laboratories Ltd. →What's new
- Consolidated net profit fell 19.6% to ₹94.88 crore for FY26.
- Revenue remained nearly flat at ₹1,805.69 crore.
- The medical devices business transfer to Morepen Medipath is now set for April 1, 2026, at ₹197.10 crore.
Why this matters
Flat revenue coupled with a sharp profit decline points to persistent margin pressure. The 35% drop in standalone profit suggests the core business is struggling more than the consolidated figures imply.
What we're watching
- Whether the medical devices business transfer improves consolidated margins.
- The impact of the ₹0.20 per share dividend on cash reserves.
- Future quarterly margin trends to see if the FY26 decline is a structural issue.
The full read
Morepen Laboratories ended FY26 with a 19.6% decline in consolidated net profit, which fell to ₹94.88 crore from ₹118.02 crore the previous year. Revenue remained stagnant at ₹1,805.69 crore, indicating that the company failed to grow its top line while facing rising costs. The standalone performance was even weaker, with profit dropping 35% to ₹66.06 crore. The board has recommended a final dividend of ₹0.20 per share. Separately, the company confirmed the transfer of its medical devices business to its subsidiary, Morepen Medipath, for ₹197.10 crore, with an effective date of April 1, 2026. These results confirm that margin compression is the primary headwind for the business. Without revenue growth, the company is struggling to maintain its bottom line. The upcoming transfer of the medical devices unit is the next test for the company's balance sheet.
Questions answered
- How did Morepen's consolidated profit compare to the previous year?
- Consolidated net profit fell 19.6% to ₹94.88 crore in FY26, down from ₹118.02 crore in the prior year.
- What was the revenue performance for the year?
- Revenue was nearly flat at ₹1,805.69 crore.
- What is the status of the medical devices business transfer?
- The company amended the appointed date for the slump sale to its subsidiary, Morepen Medipath, to April 1, 2026, with a consideration of ₹197.10 crore.
- What dividend did the board recommend?
- The board recommended a final dividend of ₹0.20 per share.
Story so far
All notes on MOREPENLAB →- 26 May 2026 · 6:49 PM IST Morepen Laboratories profit drops 20% as margins tighten
- 6d ago Morepen locks in medical devices chief with subsidiary shares